Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.

Onco Targets Ther · 2023 · PMC10155714 · PMID 37153641

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

showed a trendp=0.05actually significant

This is supported by a sub-analysis in KMT2A -rearranged patients, where TRM was similar in both groups, and OS showed a trend towards improvement (63% vs 53%, p=0.05). 11 Despite the lack of benefit in terms of OS in the total cohort, the results of this trial ultimately led to FDA approval for de novo AML patients aged ≥1 month.

also in 50,778 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.